Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

ischemic stroke

- PMLiVE

AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics

This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer

This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Datroway given FDA Priority Review for breast cancer treatment

Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need

- PMLiVE

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

Around one in five breast cancer cases are HER2-positive

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer

Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year

- PMLiVE

AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer

Around one in three patients with early-stage breast cancer are considered high risk

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer

Up to 20% of patients with metastatic breast cancer are affected by HER2-positive disease

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer

Approximately 557,000 people are diagnosed with breast cancer every year in Europe

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer

Approximately 557,000 people are diagnosed with breast cancer every year in Europe

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

AstraZeneca/Daiichi Sankyo survey reveals breast cancer misconceptions in Europe

The questionnaire gathered insights from 7,750 adults across five countries

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links